James Groark

935 total citations
19 papers, 668 citations indexed

About

James Groark is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, James Groark has authored 19 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Rheumatology, 12 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Immunology. Recurrent topics in James Groark's work include Systemic Lupus Erythematosus Research (15 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and T-cell and B-cell Immunology (5 papers). James Groark is often cited by papers focused on Systemic Lupus Erythematosus Research (15 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and T-cell and B-cell Immunology (5 papers). James Groark collaborates with scholars based in United States, United Kingdom and Italy. James Groark's co-authors include David A. Roth, Damon Bass, Anne E. Hammer, William Stohl, Norma Lynn Fox, Andrea Doria, Andreas Schwarting, Morton Scheinberg, David Gordon and C. Kleoudis and has published in prestigious journals such as Annals of the Rheumatic Diseases, SAE technical papers on CD-ROM/SAE technical paper series and BMJ Open.

In The Last Decade

James Groark

19 papers receiving 654 citations

Peers

Countries citing papers authored by James Groark

Since Specialization

Citations

This map shows the geographic impact of James Groark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Groark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Groark more than expected).

Fields of papers citing papers by James Groark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Groark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Groark. The network helps show where James Groark may publish in the future.

Co-authorship network of co-authors of James Groark

This figure shows the co-authorship network connecting the top 25 collaborators of James Groark. A scholar is included among the top collaborators of James Groark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Groark. James Groark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	OP0281 PHARMACODYNAMIC EFFECT OF SEQUENTIAL BELIMUMAB (BEL) AND RITUXIMAB (RTX) THERAPY IN PATIENTS (PTS) WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): THE PHASE 3, RANDOMISED, PLACEBO-CONTROLLED BLISS-BELIEVE STUDY 2022 ·Annals of the Rheumatic Diseases ·Y K Onno Teng, André van Maurik, Kenneth L. Clark, N. L. Fox, (unknown), James Groark, Richard W. Henderson, (unknown), David A. Roth, (unknown), (unknown), (unknown)	2
2	Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus 2021 ·Arthritis & Rheumatology ·Ellen M. Ginzler, (unknown), David D’Cruz, Richard Furie, Kathleen Maksimowicz‐McKinnon, Jim C. Oates, Mittermayer Barreto Santiago, Amit Saxena, Saira Z. Sheikh, Damon Bass, Susan W. Burriss, Jennifer Gilbride, James Groark, Michelle C. Miller, Amy Pierce, David A. Roth, Beulah Ji	72
3	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol 2019 ·BMJ Open ·Y K Onno Teng, Ian N Bruce, Betty Diamond, Richard Furie, Ronald van Vollenhoven, David Gordon, James Groark, Robert B. Henderson, Mary Oldham, Paul P. Tak	82
4	200 Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study 2019 ·Abstracts ·David D’Cruz, Kathleen Maksimowicz‐McKinnon, Jim C. Oates, Mittermayer Barreto Santiago, Damon Bass, Susan W. Burriss, Jennifer Gilbride, James Groark, Michelle C. Miller, Beulah Ji	14
5	Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study 2018 ·Lupus Science & Medicine ·Ronald van Vollenhoven, William Stohl, Richard Furie, Norma Lynn Fox, James Groark, Damon Bass, Milena Kurtinecz, Bonnie Pobiner, (unknown), Tania Gonzalez‐Rivera, David Gordon	12
6	Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus 2018 ·Arthritis & Rheumatology ·Andrea Doria, William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Ronald van Vollenhoven, Anne E. Hammer, James Groark, Damon Bass, N. L. Fox, David A. Roth, David Gordon	45
7	A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus 2018 ·Lupus ·Andrea Doria, Damon Bass, Andreas Schwarting, Anne E. Hammer, David Gordon, Morton Scheinberg, N. L. Fox, James Groark, William Stohl, C. Kleoudis, David A. Roth	23
8	SAT0231 Safety of subcutaneous belimumab in patients with systemic lupus erythematosus: a 6-month open-label extension study 2017 ·Annals of the Rheumatic Diseases ·Andrea Doria, William Stohl, Andreas Schwarting, Morton Scheinberg, Anne E. Hammer, C. Kleoudis, James Groark, (unknown), David A. Roth, Damon Bass, David Gordon	3
9	Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study 2017 ·Arthritis & Rheumatology ·William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Andrea Doria, Anne E. Hammer, C. Kleoudis, James Groark, Damon Bass, Norma Lynn Fox, David A. Roth, David Gordon	286
10	Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder 2016 ·Journal of Child and Adolescent Psychopharmacology ·Robert L. Findling, James Groark, Karen A. Tourian, (unknown), (unknown), Lingfeng Yang, Alice I. Nichols	5
11	AB0416 Reliability and Safety of A Novel Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus (SLE) 2016 ·Annals of the Rheumatic Diseases ·Saira Z. Sheikh, N. L. Fox, Anne E. Hammer, Herbert Struemper, James Groark, David A. Roth, David Gordon	1
12	Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus 2016 ·International Journal of Clinical Pharmacology and Therapeutics ·Saira Z. Sheikh, Anne E. Hammer, Norma Lynn Fox, James Groark, Herbert Struemper, David A. Roth, David Gordon	19
13	LB0001 Efficacy and Safety of Subcutaneous Belimumab plus Standard Care in Patients with Systemic Lupus Erythematosus (SLE) with Low Complement and Positive Anti-DSDNA 2016 ·Annals of the Rheumatic Diseases ·Andrea Doria, William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Ronald van Vollenhoven, Anne E. Hammer, James Groark, Damon Bass, N. L. Fox, David A. Roth, David Gordon	2
14	THU0305 Pharmacokinetics of Switching from Intravenous To Subcutaneous Belimumab for Patients with Systemic Lupus Erythematosus (SLE) 2016 ·Annals of the Rheumatic Diseases ·Saira Z. Sheikh, N. L. Fox, Anne E. Hammer, Herbert Struemper, James Groark, David A. Roth, David Gordon	1
15	Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects 2015 ·Clinical Pharmacology in Drug Development ·Herbert Struemper, (unknown), Jane Gilbert, Matthew E. Barton, (unknown), James Groark, Norma Lynn Fox, David A. Roth, David Gordon	26
16	THU0403 A Randomised, Open-Label Study to Evaluate the Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector 2015 ·Annals of the Rheumatic Diseases ·Herbert Struemper, (unknown), Jane Gilbert, (unknown), (unknown), James Groark, N. L. Fox, David A. Roth, David Gordon	1
17	Safety and Tolerability of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder 2014 ·Journal of Child and Adolescent Psychopharmacology ·Robert L. Findling, James Groark, (unknown), (unknown), Lingfeng Yang, Karen A. Tourian	12
18	Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies 2009 ·Clinical Therapeutics ·Karen A. Tourian, S. Krishna Padmanabhan, James Groark, Claudine Brisard, (unknown)	61
19	Improved Efficiency by Use of Sinter-Hardened P/M Automotive Components 2000 ·SAE technical papers on CD-ROM/SAE technical paper series ·Thomas J. Miller, James Groark, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact